Opinion|Videos|January 2, 2026
Exploring the Novel CAR T-Cell Therapy Anito-Cel in Multiple Myeloma
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, discuss the investigational CAR T-cell therapy anito-cel in multiple myeloma.
Advertisement
Episodes in this series
Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, introduce the investigational CAR T-cell therapy anitocabtagene autoleucel (anito-cel) and its potential role in multiple myeloma treatment. They discuss the therapy’s design, target selection, and early clinical rationale. Patel and Frigault outline how anito-cel may differentiate itself from currently available CAR T-cell products.
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Advertisement
Advertisement
Trending on OncLive
1
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
2
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5